Acceleron to Present at Two Upcoming Healthcare Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will present at two upcoming healthcare investor conferences.

Conference Presentation Details:

Event: SVB Leerink 8th Annual Global Healthcare Conference
Date/Time: Thursday, February 28, 2019 at 3:00 p.m. ET
Location: New York, NY

Event: Cowen & Co. 39th Annual Healthcare Conference
Date/Time: Monday, March 11, 2019 at 1:30 p.m. ET
Location: Boston, MA

A live webcast for the SVB Leerink and Cowen & Co. conference presentations may be accessed on the Investors/Media page of the Company's website at www.acceleronpharma.com. A replay of each webcast will be available approximately two hours after the event on the Acceleron website.

About Acceleron

Acceleron is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190213005109/en/

Acceleron Pharma Inc.
Investors:
Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications

Media:
Matt Fearer, 617-301-9557
Director, Corporate Communications

Source: Acceleron Pharma

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• MillworkSuite Launches AI Estimating and Direct-to-CAD Platform That Cuts Drafting Time in Half
• As Global Fuel Markets Whipsaw Through Historic Volatility, JSV Global's Jason Venturelli Calls for a New Playbook on Fuel Risk
• Top 12 Cryptos in 2026: Apeing Could Be the Best Crypto to Watch With $0.0001 Entry Price